Market size + growth trajectory
The global peptide therapeutics market crossed $45 billion in 2025 and is projected to exceed $80 billion by 2030 (per industry analyst estimates). The DTC slice — direct-to-consumer brands selling research peptides, wellness peptides, and telehealth-prescribed GLP-1 medications — is a smaller but faster-growing subset.
DTC-specific growth drivers:
- GLP-1 wave — semaglutide and tirzepatide telehealth platforms (Ro, Hims, Henry Meds, Mochi Health, Future Health, and 50+ smaller operators) drove ~$15B in DTC sales in 2025 alone.
- Research peptide expansion — BPC-157, TB-500, GHK-Cu, and dozens of other research compounds saw 200%+ year-over-year search growth as biohacker communities normalized them.
- Anti-aging + longevity adjacency — the longevity-investment boom (Bryan Johnson, Andrew Huberman content, longevity podcasts) drove top-of-funnel awareness for peptide categories that previously had no consumer presence.
The three competing layers of the market
Layer 1: FDA-approved GLP-1 telehealth
Brands like Hims, Ro, Mochi, Henry Meds, Eden, Future Health. They prescribe compounded semaglutide/tirzepatide through a network of licensed prescribers and ship from 503A/503B compounding pharmacies. They've raised hundreds of millions in venture capital and operate at $50K-$500K+/month in Meta ad spend per brand.
This layer has the easiest compliance path (FDA-approved mechanism), the highest AOV ($200-$500/month subscription), and the most competition. New entrants need ~$5M+ in capital to compete meaningfully.
Layer 2: Research peptide brands
Brands selling research-use-only peptides (GHK-Cu, BPC-157, TB-500, GLP-3 RT, and the rest of the catalog) to a research-positioning customer base. Maytrix Labs, Bioptimal, Peptide Sciences, BIOCOLLEX, Pure Peptides, and dozens of smaller operators occupy this layer.
Compliance is harder (no FDA pathway), AOV is lower ($100-$400 one-time), but margins are stronger because there's no prescriber/pharmacy markup. This layer is the bulk of the DTC peptide market by brand count.
Layer 3: Wellness-adjacent peptide brands
Brands selling copper peptide skincare, oral peptide supplements, peptide-infused recovery products. These often dodge the restricted-product label by positioning as cosmetics or supplements, but face their own compliance constraints from FDA-cosmetic rules and supplement regulations.
Smallest of the three layers commercially but the most stable from an infrastructure perspective (Shopify works, Stripe works, mainstream ad platforms work).
Who's winning in each layer
GLP-1 telehealth: Hims has commanded the most consumer mindshare and the largest ad spend. Ro and Mochi are close behind. Newer entrants like Eden and Henry Meds are growing rapidly but face brand-recognition disadvantage.
Research peptides: No single dominant player. The category is fragmented across hundreds of small brands, with the top 10-15 doing $5M-$50M in annual revenue and a long tail of smaller operators. Brand recognition is more about supplier reputation than consumer brand strength.
Wellness-adjacent: Most brands in this layer are skincare-positioned (One Skin, Truefitt, etc.) or supplement-positioned (Thorne, NOW Foods). They compete with established beauty + supplement brands rather than other peptide-specific operators.
The structural shifts ahead
FDA enforcement on GLP-1 compounding
The FDA periodically signals that compounded GLP-1 (the backbone of the telehealth GLP-1 market) may face stricter rules once name-brand semaglutide supply normalizes. If that happens — likely in 2026-2027 — many compounded GLP-1 brands will need to pivot or shut down.
Platform consolidation
As mainstream platforms tighten restricted-product enforcement, the infrastructure layer for peptide brands is consolidating around a small set of specialized agencies, payment processors, and email providers. Brands that don't build on category-specific infrastructure face higher and higher operational risk.
Compliance convergence between research + telehealth
The compliance gap between research-positioned and therapeutic-positioned peptide brands is narrowing as regulators scrutinize both. Brands operating cleanly in either lane are increasingly valuable; brands trying to straddle both lanes are increasingly at risk.
Implications for new entrants
For brands launching in 2026:
- Pick a lane explicitly: research-positioned or therapeutic-positioned. Don't straddle.
- Build on category-specific infrastructure from day one. Don't start on Shopify hoping to migrate later — that migration eats the first year of revenue.
- Budget for marketing accordingly: GLP-1 telehealth needs $50K+/month spend to compete; research peptides can launch at $9K-$15K/month and grow into the spend.
- Don't underestimate the compliance work. Operators who try to skip it are the ones who lose accounts every 30 days.
For brands needing infrastructure built for this category specifically, that's what we do — see our Build service and Meta ads service.